Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol for heart failure with reduced ejection fraction
IRCT20231115060071N1Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure (HF) comparing Allopurinol with Placebo comparator (2 arms). Primary endpoint: Blood uric acid level. Started Sep 2022; status: completed.
02
Drugs
allopurinol
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on IRCT20231115060071N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231115060071N1.